Posted by Michael Wonder on 16 Feb 2025
Galderma’s Nemluvio (nemolizumab) approved in the European Union for moderate to severe atopic dermatitis and prurigo nodularis
14 February 2025 - This approval from the European Commission is based on robust results from the Phase 3 OLYMPIA and ARCADIA clinical trial programs, showing that Nemluvio has the potential to address the significant unmet needs of patients with atopic dermatitis and prurigo nodularis.
Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union.
